GGrantIndex
Sort

82,697 grants matching vaccine development

Advancing a Glioma Immunotherapy

$981,388
Dwaine Franklin Emerich · In Cytu, Inc. · R44 · FY2013 · NS

Advanced Development of a Multivalent Vaccine Candidate for Filovirus and Lassa Fever

$981,197
Matthias Schnell · Thomas Jefferson University · N01 · FY2023 · AI

Shigella Conjugate Vaccine (SCV4) Development, Characterization, and Pre-clinical Evaluation

$981,139
Edward T. Ryan · Massachusetts General Hospital · R01 · FY2024 · AI

Pandemic Influenza Translational Research and novel universal countermeasure development

$981,112
Matthew Memoli · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI

Identification and validation of influenza host factors as therapeutic targets

$980,999
David E Root · Broad Institute, Inc. · U01 · FY2009 · AI

A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine

$980,963
Ian James Amanna · Najit Technologies, Inc. · U44 · FY2025 · AI

NCMHD-Research Center of Excellence at the University of Pittsburgh

$980,936
Stephen B. Thomas · University Of Pittsburgh At Pittsburgh · P60 · FY2008 · MD

Cryopreservation of Anopheles Embryos

$980,922
Peter F. Billingsley · Sanaria, Inc. · R44 · FY2015 · AI

Defining T cell epitopes in Dengue virus infection

$980,526
Ramila Philip · Immunotope, Inc. · R44 · FY2013 · AI

COBRE Phase III: Transitional Center for Research on Processes in Evolution

$980,492
Larry J Forney · University Of Idaho · P30 · FY2016 · GM

A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States

$980,283
Pablo Tamayo · University Of California, San Diego · U01 · FY2019 · CA

P1 - COMBINATION ACTIVATED T-CELL AND VACCINE THERAPY IN MYELOMA

$980,225
Larry W Kwak · University Of Tx Md Anderson Can Ctr · P50 · FY2010 · CA

A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1

$980,219
Erol Fikrig · L2 Diagnostics, Llc · R42 · FY2024 · AI

Host Immune Responses to Antigens of Malaria Parasites

$980,178
Carole Long · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI

Administration

$980,033
John R. Murphy · Boston University Medical Campus · UC7 · FY2015 · AI

Clinical Evaluation of Novel Adenovirus Vectors

$979,976
Raphael Dolin · Beth Israel Deaconess Medical Center · U19 · FY2008 · AI

Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG)

$979,886
David S Stephens · Emory University · UM1 · FY2020 · AI

Cape Town Clinical Trials Unit (CT-CTU) for HIV/AIDS Prevention & Treatment

$979,642
Robin Wood · University Of Cape Town · U01 · FY2007 · AI

Development of a Broad-Spectrum Inhibitor against Seasonal and Highly-Pathogenic Influenza Viruses

$979,627
Richard K. Plemper · Georgia State University · R01 · FY2021 · AI

Clinical Development of Combination Plague/Smallpox Vaccine

$979,594
Charalambos Partidos · Inviragen, Inc. · R44 · FY2009 · AI

A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1

$979,482
Erol Fikrig · L2 Diagnostics, Llc · R42 · FY2023 · AI

IMMUNITY TO STDS IN THE HUMAN MALE GENITAL TRACT

$979,478
Brigham And Women'S Hospital · P01 · FY2000 · AI

Development and Manufacture of Adjuvants for Vaccines Targeting MDR Tuberculosis

$979,306
Rhea N Coler · Access To Advanced Health Institute · U01 · FY2008 · AI

Task B13: Evaluation of MCMs directed against BSL-4 Viruses in Non-Human Primates (NHPs)

$978,859
David Beasley · University Of Texas Med Br Galveston · N01 · FY2021 · AI

SOUTH AFRICA MRC HIV PREVENTION TRIALS UNIT

$978,838
Medical Research Council Of South Africa · U01 · FY2002 · AI